Abstract: Methods are described for improving the diagnostic possibilities of diseases where oxidative NO-modifications occur, for example inflammatory conditions, cancer, Parkinson's or Alzheimer's disease, and to provide means of monitoring the effects of therapeutical measures taken towards such diseases. The invention enables the detection of disease specific catabolic markers related to oxidative NO-modifications, utilizing an immunoassay comprising antibodies directed against nitrated and non-nitrated epitopes characteristic of a specific protein.
Type:
Grant
Filed:
June 27, 2008
Date of Patent:
March 29, 2011
Assignee:
Universite De Liege
Inventors:
Jean-Yves Reginster, Michelle Deberg, Yves Henrotin, Stephan Christgau
Abstract: A method extracts out of an aqueous solution, concentrate and/or reformulate [18F] fluorides without any evaporation step. The eluting solution is a low water content, preferably <3% water, organic solution containing at least: a first compound (A) which is a tertiary alcohol-function bearing molecule, a second compound (B) which is a phase transfer agent suitable for radiolabeling and which is necessary to the anion exchange process.
Type:
Application
Filed:
February 19, 2008
Publication date:
January 13, 2011
Applicants:
TRASIS S.A., UNIVERSITE DE LIEGE
Inventors:
Joel Aerts, Christian Lemaire, Steve Lignon, Andre Luxen, Jean-Luc Morelle, Gauthier Philippart, Samuel Voccia
Abstract: This invention relates to a Vascular Endothelial Growth Factor (VEGF) polypeptide, which polypeptide lacks an amino acid sequence encoded by exon 5 of the VEGF gene. This variant of VEGF is capable of eliciting activities associated with VEGF whilst showing resistance to proteolytic degradation. The invention provides uses of this protein and nucleic acid sequences from the encoding genes in the diagnosis, prevention and treatment of disease.
Type:
Application
Filed:
January 18, 2007
Publication date:
November 11, 2010
Applicant:
UNIVERSITE DE LIEGE
Inventors:
Alain Colige, Pierre Mineur, Charles Lambert
Abstract: The invention provides the use of a cyclodextrin compound for the manufacturing of a medicament for the treatment or prevention of bronchial inflammatory diseases, particularly for asthma.
Abstract: The present invention is related to a method to obtain reactive [18F] fluorides in an organic medium suitable for radiolabelling without any azeotropic evaporation step, by the use of a solid phase extraction column containing a modified non-ionic solid support.
Type:
Application
Filed:
April 22, 2008
Publication date:
September 30, 2010
Applicants:
Trasis S.A., Universite de Liege
Inventors:
Samuel Voccia, Joél Aerts, Christian Lemaire, André Luxen, Jean-Luc Morelle, Gauthier Philippart
Abstract: The present invention is related to a combined method and kit (or device) for the sequential measurement of the enzymatically active fraction and the total amount of an enzyme [(such as myeloperoxidase (MPO)] in a sample, and that find improved applications in veterinary and human health fields.
Abstract: A method to extract out of an aqueous solution, concentrate and/or reformulate [18F] fluorides without any evaporation step wherein the eluting solution is a organic solution having a water content <3%. The solution contains at least: an organic solvent suitable for the subsequent radiolabelling reaction; a first compound (A) which is a molecule containing at least one acidic hydrogen and a second compound (B) which is an organic base sufficiently strong to be able to tear off the acidic hydrogen of the first compound (A) in an acid-base reaction leading to the formation of an organic salt (S).
Type:
Application
Filed:
July 1, 2008
Publication date:
August 5, 2010
Applicants:
TRASIS S.A., UNIVERSITE DE LIEGE
Inventors:
Christian Lemaire, Samuel Voccia, Joël Aerts, André Luxen, Jean-Luc Morelle, Gauthier Philipart
Abstract: The present invention refers to a recombinant nucleotide sequence which codes upon expression for at least a part of a bifunctional hybrid active-site serine ?-lactamase protein, wherein the ?-lactamase protein is bearing at least one heterologous sequence, wherein in that the hybrid protein is having two functions, the first function is associated with the ?-lactamase portion and the second function is associated with the heterologous sequence having a biological function which is different from the first function.
Type:
Grant
Filed:
January 17, 2005
Date of Patent:
June 29, 2010
Assignee:
Universite de Liege
Inventors:
Fabrizio Giannotta, Patrice Filee, Moreno Galleni, Jean-Marie Frere, Bernard Joris, Alain Brans, Nadia Ruth
Abstract: The present invention refers to a method for determining the genotype of an individual at the 5p13.1 Crohn's disease risk locus, the method comprising: providing a sample from the individual; determining whether a DNA sequence corresponding to a DNA sequence polymorphism located between coordinated 40,300,000 and 40,600,000 of human chromosome (coordinates corresponding to the march 2006 assembly of the human genome) is present in the sample; and determining the nature of the DNA sequence polymorphism genotype located between coordinated 40,300,000 and 40,600,000 of human chromosome as it relates to the genetic risk to develop Crohn's disease.
Type:
Application
Filed:
February 29, 2008
Publication date:
June 3, 2010
Applicants:
UNIVERSITE DE LIEGE, CENTRE HOSPITALIER UNIVERSITAIRE DE LIEGE, COMMISSARIAT A L'ENERGIE ATOMIQUE
Inventors:
Michel Georges, Edouard Louis, Cecile Libioulle, Mark Lathrop
Abstract: The present invention relates to the use of N-phosphonylmethoxyethyl nucleoside analogs for manufacturing a medicament for the treatment or prevention of Koi Herpes virus infections in fish, especially in carps.
Type:
Application
Filed:
May 16, 2008
Publication date:
June 3, 2010
Applicants:
Katholieke Universiteit Leuven, Universite de Liege
Inventors:
Berenice Costes, Johan Neyts, Alain Vanderplasschen
Abstract: A method for improving the diagnostic assessment of cartilage degenerative processes, and to provide means of monitoring the effects of therapeutical measures taken towards arthritic diseases in most mammals utilizes an immunoassay to detect fragments of collagen type II resulting from collagenase activity comprising an antibody directed against an epitope comprised in the amino acid sequence HRGYPGLDG (SEQ ID NO:1), located in the helical region of collagen type II.
Type:
Grant
Filed:
August 7, 2008
Date of Patent:
June 1, 2010
Assignee:
Universite de Liege
Inventors:
Jean-Yves Reginster, Michelle Deberg, Yves Henrotin, Stephan Christgau
Abstract: The present invention refers to a pharmaceutical composition comprising an isolated antiangiogenic peptide or a recombinant protein comprising the antiangiogenic peptide, wherein the peptide is between 11 and 40 amino acids in length and having antiangiogenic activity, the peptide comprising the amino acid sequence: X1-X2-X3-X4-X5-X6-X7-X8-X9-X10-X11-X12-X13-X14, wherein X1 is any amino acid residue compatible with forming a helix; X2 is an amino acid residue of: Leu, Ile, Val; X3 is an amino acid residue of: Arg, Lys, His, Ser, Thr; X4 is an amino acid residue of: Ile, Leu, Val; X5 is any amino acid residue compatible with forming a helix; X6 is an amino acid residue of: Leu, Ile, Val; X7 is an amino acid residue of: Leu, Ile, Val, Ser, Thr; X8 is any amino acid residue compatible with forming a helix; X9 is any amino acid residue compatible with forming a helix; X10 is an amino acid residue of: Gln, Glu, Asp, Arg, His, Lys, Asn; X11 is an amino acid residue of: Ser, Thr; X12 is an amino acid residue of: Trp
Type:
Grant
Filed:
August 11, 2005
Date of Patent:
February 2, 2010
Assignees:
Universite de Liege, Faculte Universitaire des Sciences Agronomiques de Gembloux
Inventors:
Joseph Martial, Ingrid Struman, Ngoc-Quynh-Nhu Nguyen, Robert Brasseur, Laurence Lins
Abstract: A new, quick, simple, efficient, safe, and reproducible surgical technique for the treatment of female urinary incontinence, in which the posterior urethra is suspended using a tape passed through the obturator orifices from inside (underneath the urethra) to outside (thigh folds). A variety of specifically designed surgical instruments are utilized to perform this operative procedure.
Type:
Application
Filed:
August 12, 2009
Publication date:
December 10, 2009
Applicant:
Universite de Liege and centre Hospitalier Universitaire de Liege
Abstract: A new, quick, simple, efficient, safe, and reproducible surgical technique for the treatment of female urinary incontinence, in which the posterior urethra is suspended using a tape passed through the obturator orifices from inside (underneath the urethra) to outside (thigh folds). A variety of specifically designed surgical instruments are utilized to perform this operative procedure.
Type:
Grant
Filed:
May 27, 2004
Date of Patent:
November 3, 2009
Assignees:
Universite De Liege, Centre Hospitalier Universitaire De Liege
Abstract: Use of Bis 1,2,3,4-tetrahydroisoquinoline derivatives represented by formula (I) as SK channel blockers and for the preparation of a medicament useful for the treatment of disorders of the central nervous system.
Type:
Application
Filed:
March 3, 2007
Publication date:
April 9, 2009
Applicant:
UNIVERSITE DE LIEGE
Inventors:
Amaury Graulich, Jean-Francois Liegeois, Jacqueline Moreau, Vincent Seutin
Abstract: The invention relates to novel benzopyran derivatives of formula I, to their method of production, to composition comprising the derivatives and use thereof.
Type:
Grant
Filed:
January 21, 2005
Date of Patent:
March 24, 2009
Assignees:
Universite de Liege, Universite Libre de Bruxelles
Inventors:
Sophie Sebille, Bernard Pirotte, Stéphane Boverie, Pascal De Tullio, Philippe Lebrun, Marie-Hélène Antoine
Abstract: A method for improving the diagnostic assessment of cartilage degenerative processes, and to provide means of monitoring the effects of therapeutical measures taken towards arthritic diseases in most mammals utilizes an immunoassay to detect fragments of collagen type II resulting from collagenase activity comprising an antibody directed against an epitope comprised in the amino acid sequence HRGYPGLDG (SEQ ID NO:1), located in the helical region of collagen type II.
Type:
Application
Filed:
August 7, 2008
Publication date:
February 12, 2009
Applicant:
Universite de Liege
Inventors:
Jean-Yves Reginster, Michelle Deberg, Yves Henrotin, Stephan Christgau
Abstract: The invention relates to a mucoadhesive pharmaceutical composition comprising a polymer and a chemoattractant wherein the pH of the composition is greater than 6 which is useful in the treatment of a anogenital or oral disease, particularly an anogenital or oral disease cause by the human papillomavirus.
Type:
Application
Filed:
December 12, 2005
Publication date:
November 27, 2008
Applicant:
UNIVERSITE DE LIEGE
Inventors:
Ludivine Herman, Pascale Hubert, Philippe Delvenne, Jacques Boniver, Brigitte Evard, Luc Delattre, Francis Frankenne, Agnes Noel, Jean-Michel Foidart
Abstract: A probiotic composition comprising a Bifidobacterium strain which has DNA sequence homology of greater than 40% to Bifidobacterium GC56, wherein Bifidobacterium GC56 was deposited at the Collection Nationale de Cultures de Micro-organismes (CNCM, Institut Pasteur) on 9 Dec. 2004 with accession number CNCM 1-3342.
Type:
Application
Filed:
March 31, 2006
Publication date:
November 6, 2008
Applicant:
UNIVERSITE DE LIEGE
Inventors:
Georges Daube, Veronique Delcenserie, Francoise Gavini
Abstract: The present invention is related to accurate detection methods for the measurement only of myelopexidase (MPO) levels or neutrophils, preferably equine neutrophils, in complex biological samples. The present invention is further related to ELISA and SIEFED assays for such detection. SIEFED detection sensitivity of active peroxidase activity was found to be enhanced by the addition of nitrite. Such MPO measurement finds its use in many applications such as the prediction, diagnosis and/or monitoring of pathologies correlated with neutrophil activation and/or destruction; the evaluation of drugs and/or immunomodulators; the assessment of immune responses, either natural and/or after treatment with immunomodulators and/or drugs; and the study of cells and their ability to fight microorganisms and/or to destroy them.